20/12/2022 - General information
The Board of Trustees of the Spanish Psychiatry and Mental Health Foundation has chosen Dr. Víctor Pérez, head of the Psychiatry Department of the Hospital del Mar and coordinator of the Mental Health Research Group of the Hospital del Mar Medical Research Institute, as the new president of the organization. This appointment comes after Dr. Perez left his position as president of the executive committee of the Spanish Society of Psychiatry and Mental Health. As the highest representative of the foundation, Dr. Pérez will be responsible for representing the entity, chairing the meetings of its board of trustees and executing the agreements reached. The aim of its activity is to contribute to the knowledge, development and improvement of psychiatry and mental health and the disciplines that are linked to it.
Més informació "Dr. Víctor Pérez will chair the Spanish Foundation of Psychiatry and Mental Health."
02/12/2022 - Press release
The Hospital del Mar Medical Research Institute is leading the study that will evaluate whether a new molecule can be used to improve the cognitive performance of people with Down syndrome. The study is part of the ICOD project for the improvement of cognition in Down syndrome, promoted by the European Union, which is funding a project of this type for the first time. The treatment has already passed the trial phase with volunteers without Down syndrome, which sought to certify the safety and tolerability of the medicine. In this new phase, the safety of the treatment in people with Down syndrome will be validated and the first indications of effectiveness will be obtained. It is estimated that results may be available by mid-2023.
01/12/2022 - General information
The first EU-wide STAR treatment registry is now open! STOPSTORM is now accepting anonymized data from our 30 partner organizations across 8 European countries. Later, we will expand this to even more centers across the EU. STOPSTORM aims to collect data from over 300 patients into the registry by 2025. These data will establish the indication, safety and efficacy of STAR for the treatment for Ventricular Tachycardia. What is STAR treatment? STAR is a non-invasive radiotherapy technique used to treat dangerously fast heart rhythm, called ventricular tachycardia, or VT. A similar radiotherapy technique has been used for a decade to treat lung cancer.
30/11/2022 - General information
The head of the Colon and Rectal Surgery Unit in the Surgery Department at Hospital del Mar and a researcher in the Cancer Research Programme at the Hospital del Mar Medical Research Institute received this professional accolade on 28 November. Dr. Marta Pascual, head of the Colon and Rectal Surgery Unit in the Surgery Service at Hospital del Mar and a researcher in the Cancer Research Programme at the Hospital del Mar Medical Research Institute, was one of the people honoured through the Official College of Doctors of Barcelona (Col·legi Oficial de Metges de Barcelona; COMB) Professional Excellence Award.
23/11/2022 - Institutional news
This list is compiled by the analysis company Clarivate. It includes almost 7,000 researchers from around the world, selected as the most influential based on the number of times they have been cited in scientific publications published between 2011 and 2021.
18/11/2022 - General information
A team of researchers from the Hospital del Mar Medical Research Institute has created a model for predicting individual breast cancer risk that could be used to create personalised breast cancer screening strategies. The research, presented at the 13th European Breast Cancer Conference, could make breast screening programmes more effective and ultimately improve survival rates. It could also mean fewer people suffering from 'false positives' (when screening tests indicate cancer, but other tests show there is none) and 'overdiagnosis' (when people are diagnosed and treated for a cancer that is extremely slow growing and has not caused any problems in their lives).
16/11/2022 - Press release
A study led by the Hospital del Mar Medical Research Institute, the Barcelonaβeta Brain Research Centre (BBRC), a research unit from the Pasqual Maragall Foundation, and the University of Gothenburg, has compared the validity of nine biomarkers for the day-to-day diagnosis of Alzheimer's disease in hospital centres. The work involved a cohort of patients from Hospital del Mar with various neurological pathologies. The researchers analysed the presence of nine variants of the Tau protein in blood samples from these people. Some of these blood markers are just as useful for detecting Alzheimer's as those measured in the reference test used, namely the analysis of cerebrospinal fluid obtained by lumbar puncture. Less invasive plasma biomarker determinations than those performed after a lumbar puncture may provide a tool for improving the diagnosis of Alzheimer's disease and determining which individuals should undergo further testing to confirm the diagnosis. The work has been published in the leading journal in this field, Alzheimer's & Dementia.
15/12/2022 - General information
The study, led by Dr. Xavier Nogués, has received one of the two biomedical research grants awarded by this organization, with a total endowment of 650,000 euros. The award ceremony took place in Madrid on December 14. A project to identify the factors that affect the risk of developing a state of fragility, headed by Dr. Xavier Nogués, director of the Clinical Translational Research Program at the Hospital del Mar Medical Research Institute and head of the Internal Medicine Department at the Hospital del Mar, has received one of the two grants for biomedical research awarded by the Francisco Soria Melguizo Foundation. These grants total 650,000 euros and were awarded on December 14 at a ceremony held at the Royal National Academy of Pharmacy in Madrid.
30/09/2022 - General information
An international collaborative study involving the Hospital del Mar Medical Research Institute and the Hospital del Mar has analyzed data from over 200,000 stroke patients and more than two million control individuals from five different ancestries. This study has associated 89 genes, of which 69 were previously unknown, with stroke and its subtypes. The research provides crucial insights to guide future biological investigations into the processes leading to this condition. Additionally, it reveals that some of these genes could potentially serve as targets for drugs to prevent or treat this disease. It also offers genetic prediction tools, improved and validated for the first time in non-European populations, to guide the development of new drugs.
07/11/2022 - General information
At the same time, the head of the Haematological Cytology section of the Pathology Service of the Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute, is secretary of the board of directors of the Spanish Group for Haematological Cytology and also holds the same position in the Spanish Group of Myelodysplastic Syndromes.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
